HtrA1 防止和逆转α-synuclein 聚合,使其无毒和无能力播种
Sheng Chen1, Anuradhika Puri2, Braxton Bell1
1Washington University in St. Louis.
Research square
|September 7, 2023
概括
HtrA1蛋白抑制了α-synuclein (α-syn) 的预先形成的纤维的聚合和分解,α-syn是帕金森病 (PD) 中的关键蛋白质. 这种活动独立于其蛋白酶功能,表明HtrA1是神经退行性疾病的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 帕金森病 (PD) 涉及α-syn 核素 (α-syn) 的错误折叠和聚合.
- 在阿尔茨海默氏症 (AD) 中,HtrA1蛋白酶降解tau;HtrA2突变与PD有关.
- 在ALS和FTD中涉及的FUS和TDP-43聚合.
研究的目的:
- 研究HtrA1在抑制和分解α-syn和其他与疾病相关的蛋白质聚合物的作用.
- 为了确定HtrA1的蛋白酶活性是否为其抗聚合效应所必需.
- 确定HtrA1影响α-syn结构和聚合的机制.
主要方法:
- 在体外测定以评估α-syn,FUS和TDP-43聚合抑制的HtrA1.1.
- 使用蛋白分解活性和非活性HtrA1结构的实验.
- 哺乳动物生物传感器细胞测试以评估α-syn播种活动.
- 对HtrA1-修饰的α-syn进行结构分析,重点关注NAC域.
- 主要神经元模型研究HtrA1对α-syn聚合和酸化的影响.
主要成果:
- HtrA1 抑制了α-syn,FUS 和 TDP-43.3 的聚合.
- 蛋白酶域的HtrA1是必要的和足够的聚合抑制,独立于蛋白质分解活性.
- HtrA1分解预先形成的α-syn纤维,并防止新聚合物的播种.
- HtrA1通过准NAC域来重塑α-syn.
- 活跃和不活跃的HtrA1都能排毒α-syn,并防止神经元中的高酸化.
结论:
- HtrA1 防止和逆转多种与疾病相关的蛋白质的聚合,包括α-syn.
- HtrA1的抗聚合机制独立于其蛋白质分解功能.
- HtrA1对NAC域的向对其对α-syn.的影响至关重要.
- HtrA1代表了PD,ALS和FTD等各种神经退行性疾病的潜在治疗标.
更多相关视频
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
8.3K
09:16Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
7.6K
相关概念视频
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:32Export of Misfolded Proteins out of the ER
3.6K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.6K